Hospital discharge treatments after an acute event: Evidence for a systems approach to prevention

Coronary Artery Disease

Volumn 17, Issue 3, 2006, Pages 239-241

  Polk, Donna M ^a,b   Watson, Karol ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hospital discharge; Lipid lowering; Undertreatment

Indexed keywords

ABCIXIMAB; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; PRAVASTATIN; STATIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEALTH CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

ACUTE DISEASE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT COMPLIANCE; PATIENT DISCHARGE; PATIENT READMISSION; RISK FACTORS;

EID: 33748304092     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200605000-00006     Document Type: Short Survey

References (28)

1. American Heart Association. 2005 Heart and stroke statistical update. Dallas, Texas: American Heart Association; 2005.
2. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline number 10. Rockville, Maryland: Agency for Health Care Policy and Research (AHCPRP); 1994.
3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D. et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 286:1711-1817.
4. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute Myocardial infarction and 1-year survival. JAMA 2001; 285:430-436.
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
6. Person TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-467. • Assessment of compliance in an outpatient setting illustrating the treatment gap.
7. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH, Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001; 87:819-822. • Inpatient comprehensive program which resulted in substantial change in patient compliance with outpatient medical regime.
8. Simpson E, Beck C, Hugues R, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage compliance, and persistence. Am Heart J 2003; 145:438-444.
9. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Indulis R, Ho M, et al.Effectiveness of statin therapy in adults with coronary heart disease. Arch Int Med 2004; 164:1427-1436.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
11. Armtz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer, Beneficial effects of pravastatin (+/- cholestyramine/niacin) titrated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease L-CAD Study). Am J Cardiol 2000; 86:1293-1298.
12. Walter DH, Fichtlscherer S, Britten MB, Auch-Schwelk W, Schachinger. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002; 89:1-6.
13. Lee CH, de Feyter P, Serruys PW, Saia F, Lemos PA, Goedhart D, et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol Intervention Prevention Study (LIPS). Heart 2004; 90:1156-1161.
14. Aronow HD, Topol EJ, Row MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observation study. Lancet 2001; 357:1063-1068.
15. Lesaffre E, Kocmanova D, Lemos PA, Disco CM, Serruys PW. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003; 25:2431-2447.
16. Spencer F, Fonarow GC, Frederick PD, Wright RS, Every N, Goldbert RJ, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Int Med 2004; 164:2162-2168.
17. Fonarow GC, French WJ, Parsons LS, Sun J, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103:38-44.
18. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83:1303-1307.
19. Khanderia U, Faulkner TV, Townsend KA, Streetman DS. Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting. Am J Health-System Pharm 2002; 59:548-551.
20. EUROASPIRE Study Group.A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18:1569-1582.
21. Ades PA, Waldmann ML, McCann WJ, Weaver SO, Predictors of cardiac rehabilitation participation in older coronary patients. Arch Intern Med 1992; 152:1033-1035.
22. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Int Med 2003; 163:2576-2582.
23. Frolkis JP, Blackburn GG, Pearce GL, Sprecher DL. Usefulness of providing physicians the results of risk factor assessments and treatment recommendations at discharge after coronary artery bypass grafting. Am J Cardiol 2000; 86:455-457.
24. Grace SL, Evindar A, Kung T, Scholey P, Stewart DE. Increasing access to cardiac rehabilitation. J Cardiopulm Rehabil 2004; 24:171-174.
25. Khanderia U, Townsend DA, Eagle K, Prager R. Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol. Chest 2005; 127:455-463.
26. Ansari MN, Shilpak MG, Heldenreich PA, Massie BM. Strategies to improve guideline adherence: a randomized clinical trial. JACC 2002; 39(suppl. A):849-850.
27. Lappe JM, Muhlestein JB, Lappe DL, Badger RS, Bair TL, Brockman R, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Int Med 2004; 141:446-453.
28. Fonarow GC, Gawlinski A, Watson KA, Moughrabi S. Sustained improvement in the treatment of cardiovascular disease by implementation of a Cardiovascular Hospitalization Atherosclerosis Management Program: CHAMP. Circulation 2001; 104:II711.